Hospital
Olean General Hospital
Olean General Hospital was paid $3.17M by Medicaid between Jan 2018 and Nov 2024, across 164 billing codes. Its largest line is 99283, emergency room visit (moderate) — 43% of everything it billed.
33Billing provider infoOLEAN GENERAL HOSPITAL
BRADFORD, PA 16701
BRADFORD, PA 16701
33aNPI1578569885assigned 06/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.17M
24GClaims114,647
24DCodes billed164
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#74 of 154
Median peer was paid$2.82M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 163 | $7K | |
| 2019 | 1,135 | $50K | |
| 2020 | 11,084 | $271K | |
| 2021 | 52,129 | $1.31M | |
| 2022 | 19,880 | $642K | |
| 2023 | 19,594 | $596K | |
| 2024incomplete | 10,662 | $299K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 43% | 15,177 | 14,482 | $1.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.7% | 5,020 | 4,872 | $276K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.6% | 3,090 | 2,907 | $242K |
| 80053 | Comprehensive metabolic panel | 2.9% | 9,170 | 8,216 | $93K |
| 80050 | General health panel | 2.7% | 2,132 | 2,096 | $86K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.6% | 4,182 | 860 | $83K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.4% | 901 | 863 | $76K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 1,302 | 1,161 | $73K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 368 | 349 | $58K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 2,257 | 1,975 | $45K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 9,463 | 8,389 | $37K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,575 | 1,385 | $36K |
152 more codes
| 87275 | 1.1% | 3,256 | $34K | |
| 87279 | 1.0% | 2,790 | $33K | |
| 80061 | Lipid panel | 1.0% | 2,618 | $32K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,200 | $28K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 477 | $26K |
| 99285 | Emergency room visit (most serious) | <1% | 205 | $25K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 230 | $24K |
| 86756 | <1% | 1,226 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 265 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 523 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,390 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,054 | $18K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 237 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,332 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 718 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 620 | $12K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 330 | $12K |
| 81003 | <1% | 5,276 | $12K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 139 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 358 | $9K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 212 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,470 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,241 | $9K |
| 83880 | <1% | 333 | $8K | |
| 99223 | Prolong inpt eval add15 m | <1% | 50 | $8K |
| 84484 | <1% | 1,204 | $8K | |
| 84439 | <1% | 1,124 | $8K | |
| 87070 | <1% | 1,147 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 718 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 44 | $7K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 165 | $7K |
| 87430 | <1% | 1,075 | $7K | |
| 86631 | <1% | 693 | $7K | |
| 0001A | <1% | 151 | $6K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 222 | $6K |
| 87088 | <1% | 849 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 999 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 34 | $6K |
| 83735 | <1% | 1,163 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 116 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 130 | $5K |
| 82607 | <1% | 451 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 90 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 116 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 122 | $5K |
| 82728 | <1% | 414 | $5K | |
| 80346 | <1% | 339 | $4K | |
| 73564 | <1% | 216 | $4K | |
| 83690 | <1% | 1,152 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 616 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 91 | $4K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 79 | $4K |
| 0002A | <1% | 112 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 167 | $4K |
| 87077 | <1% | 517 | $3K | |
| 73610 | <1% | 187 | $3K | |
| 85730 | <1% | 613 | $3K | |
| 87797 | <1% | 70 | $3K | |
| 85610 | <1% | 1,014 | $3K | |
| 87186 | <1% | 383 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,318 | $3K |
| 86803 | <1% | 157 | $3K | |
| 71250 | <1% | 49 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 45 | $3K |
| 83540 | <1% | 382 | $3K | |
| 84145 | <1% | 177 | $3K | |
| 87040 | <1% | 241 | $3K | |
| 76641 | <1% | 59 | $2K | |
| 85379 | <1% | 285 | $2K | |
| 84703 | <1% | 277 | $2K | |
| 86618 | <1% | 55 | $2K | |
| 73630 | <1% | 203 | $2K | |
| 85027 | <1% | 271 | $2K | |
| 87081 | <1% | 385 | $2K | |
| 81025 | <1% | 490 | $2K | |
| 83615 | <1% | 454 | $2K | |
| 84436 | <1% | 223 | $2K | |
| 87390 | <1% | 176 | $2K | |
| 84702 | <1% | 110 | $2K | |
| 82043 | <1% | 253 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 27 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 103 | $2K |
| 73110 | <1% | 161 | $2K | |
| 83605 | <1% | 280 | $2K | |
| 76536 | <1% | 42 | $2K | |
| 73030 | <1% | 125 | $2K | |
| 84466 | <1% | 94 | $2K | |
| 87660 | <1% | 73 | $1K | |
| 86850 | <1% | 197 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 57 | $1K |
| 83550 | <1% | 275 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 196 | $1K |
| 73130 | <1% | 96 | $1K | |
| 80354 | <1% | 28 | $1K | |
| 80329 | <1% | 117 | $1K | |
| 82570 | <1% | 153 | $1K | |
| 82746 | <1% | 153 | $923.43 | |
| 85652 | <1% | 303 | $818.06 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 105 | $775.30 |
| 86592 | <1% | 185 | $696.49 | |
| 74018 | <1% | 60 | $686.73 | |
| 87276 | <1% | 369 | $672.65 | |
| 86038 | <1% | 42 | $665.25 | |
| 82150 | <1% | 157 | $644.49 | |
| 73502 | <1% | 43 | $579.07 | |
| 97597 | <1% | 52 | $563.81 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $561.65 |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $561.09 |
| 84481 | <1% | 24 | $557.14 | |
| 86901 | <1% | 153 | $548.82 | |
| 86900 | <1% | 154 | $541.87 | |
| 76801 | <1% | 15 | $455.85 | |
| 87340 | <1% | 30 | $452.18 | |
| 86787 | <1% | 27 | $422.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,289 | $422.45 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 24 | $397.70 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $366.50 |
| 82553 | <1% | 47 | $351.33 | |
| 85007 | <1% | 82 | $350.52 | |
| 82962 | <1% | 170 | $341.50 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 17 | $309.73 |
| 36591 | <1% | 208 | $294.27 | |
| 82550 | <1% | 48 | $264.98 | |
| 84153 | <1% | 14 | $258.76 | |
| 72110 | <1% | 12 | $222.75 | |
| 73090 | <1% | 15 | $216.41 | |
| 80076 | <1% | 25 | $212.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,566 | $200.48 |
| 86039 | <1% | 12 | $179.25 | |
| 83655 | <1% | 15 | $163.50 | |
| 82248 | <1% | 28 | $150.00 | |
| 82247 | <1% | 19 | $136.82 | |
| 97607 | <1% | 15 | $123.62 | |
| 87075 | <1% | 13 | $119.50 | |
| 86141 | <1% | 12 | $115.80 | |
| 87205 | <1% | 25 | $111.38 | |
| 86140 | <1% | 38 | $107.40 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 57 | $99.33 |
| 82950 | <1% | 14 | $90.42 | |
| 86308 | <1% | 14 | $89.76 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 122 | $84.22 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,144 | $82.17 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 27 | $59.97 |
| 85018 | <1% | 14 | $48.90 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 58 | $34.08 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 81 | $20.50 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14 | $15.90 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $8.52 |
| 90715 | 0% | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 12 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 43 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOWENS, JILL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Olean General Hospital | Olean, NY | $22.91M |
| Health System Physician PC | Olean, NY | $945K |
| Olean General Hospital | Bradford, PA | $349K |
| Olean General Hospital | Olean, NY | $130K |
| Olean General Hospital | Bradford, PA | $59K |
| Olean General Hospital | Bradford, PA | $23K |
| Olean General Hospital | Smethport, PA | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.